News

In connection with the closing of this acquisition, DOR will issue the stockholders of Gastrotech $9 million in shares of DOR common stock. A further $30 million in

Since many hypertensive patients require combination therapy in order to reach optimal blood pressure levels, combining two effective agents into a single drug product may simplify multi-drug treatment

The study of 3,600 patients on hemodialysis, found no reduction in S aureus types 5 and 8 infections in the Staphvax group as compared to the placebo group.

Under the terms of the collaboration, AstraZeneca will evaluate a number of prostate cancer drug targets discovered by Caprion. AstraZeneca will obtain exclusive, worldwide rights to develop and

REP 9 has potent activity against influenza when given either in prophylaxis or as therapy. In tissue culture, REP 9 showed potent activity against over 10 strains of

At present Tamiflu is believed to be the most effective treatment against avian flu. The product was originally co-developed with the US firm Gilead Sciences and is indicated

Roche currently markets daclizumab for induction transplant therapy as Zenapax. Roche and Protein are developing a new subcutaneous daclizumab (daclizumab s.c.) formulation for use in phase II clinical

The crossover study compared the pharmacokinetics between equal strengths of BioDelivery Sciences’s (BDSI’s) oral adhesive disc (called Bema Fentanyl) and Actiq, a lozenge formulation of fentanyl. The study

The trial will be conducted at multiple centers in the US and will compare Heplisav to GlaxoSmithKline’s Engerix-B vaccine. The trial is designed to yield safety, tolerability, pharmacokinetic